The results are based on the first-ever trial of any Covid-19 jabs in kids under 12 years of age, Pfizer said in a statement.

 

The Phase 2/3 study enrolled 2,268 children who were 5 to 11 years of age and were given a two-dose regimen of 10 micrograms 21 days apart. A smaller dose than the 30 microgram dose is used for people 12 and older.

 

The antibody responses in the participants given 10 microgram doses were comparable to those recorded in a previous Pfizer-BioNTech study in people 16 to 25 years of age immunised with 30 microgram doses.

 

"Over the past nine months, hundreds of millions of people ages 12 and older from around the world have received our Covid-19 vaccine. We are eager to extend the protection afforded by the vaccine to this younger population, subject to regulatory authorisation, especially as we track the spread of the Delta variant and the substantial threat it poses to children," Pfizer Chairman and Chief Executive Officer, Albert Bourla, said in the statement.

 

Further, the Covid-19 vaccine was found to be well tolerated, with side effects generally comparable to those observed in participants 16 to 25 years of age.

 

The data will be submitted "as soon as possible" to the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and other regulators, Pfizer said.

 

The company is also expected to soon share the result of the trial on children aged 2-5 years of age and children 6 months to 2 years of age.

 

The new data comes as children made up an increased portion of cases in many US states and parents are anxious to get their children vaccinated, especially as schools reopen.

 

"Since July, pediatric cases of Covid-19 have risen by about 240 per cent in the US -- underscoring the public health need for vaccination. These trial results provide a strong foundation for seeking authorisation of our vaccine for children 5 to 11 years old, and we plan to submit them to the FDA and other regulators with urgency," Bourla said.

 

So far, of the vaccines available in the US, only the Pfizer-BioNTech shots have been cleared by the FDA for people as young as 12, while Moderna's and Johnson & Johnson's vaccines have been authorised for adults.